After posterior cervical fusion, pooled agonist use including liraglutide was linked to lower pseudarthrosis rates at all reported times.
In plain wordsPooled drug use including liraglutide was linked to fewer failed posterior fusions than no agonist use.
- Peptide
- Liraglutide
- Outcome
- DecreasePosterior fusion pseudarthrosis
- Study
n = 2,756
- Comparator
- No GLP-1 agonist prescription
- Outcome group
- Bone and joint · Musculoskeletal
Measurements
- Pseudarthrosis rate
- 13.21%
- GLP-1 agonist cohort, posterior fusion, 6 months
- Pseudarthrosis rate
- 22.28%
- No GLP-1 agonist cohort, posterior fusion, 6 months
- Pseudarthrosis rate
- 14.37%
- GLP-1 agonist cohort, posterior fusion, 1 year
- Pseudarthrosis rate
- 24.45%
- No GLP-1 agonist cohort, posterior fusion, 1 year
- Pseudarthrosis rate
- 16.87%
- GLP-1 agonist cohort, posterior fusion, 2 years
- Pseudarthrosis rate
- 24.43%
- No GLP-1 agonist cohort, posterior fusion, 2 years
Source sentences
Posterior postoperative pseudarthrosis rates were also significantly decreased in the GLP-1 agonist cohort versus the non-GLP-1 agonist cohort at 6-months (13.21% vs. 22.28%; P <0.001), 1-year (14.37% vs. 24.45%; P <0.001), and 2-years (16.87% vs. 24.43%; P <0.001).
1 context sentence(design, population, supporting numbers)
Patients prescribed liraglutide, pramlintide, tirzepatide, semaglutide, lixisenatide, or dulaglutide within 1 year of surgery were propensity matched to patients without GLP-1 agonist prescriptions.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.